Anne Eaton

About

Anne Eaton, PhD, MS, is an Assistant Professor in the Division of Biostatistics & Health Data Science at the School of Public Health, University of Minnesota. She develops statistical methods to understand processes happening over time that cannot be observed completely due to complex observation and/or censoring processes. Her work is driven by common issues arising in cancer research, including multiple related time-to-event endpoints and data collection schedules that differ across patients. In her methodological and collaborative work, she strives to translate data into information that is meaningful to researchers, doctors, and patients. Her expertise includes survival analysis, multistate models, non-parametric methods, and clinical trial design. Dr. Eaton is a member of the Masonic Cancer Center and has been recognized with the Delta Omega Honorary Society in Public Health in 2020. She holds a PhD and MS in Biostatistics from the University of Minnesota and a BA in Mathematics from Grinnell College. She teaches in the Biostatistics (MPH, MS, PhD) program at the School of Public Health.

Research topics

• Internal medicine
• Medicine
• Machine Learning
• Oncology
• Computer Science
• Statistics
• Immunology
• Mathematics

Selected publications

• Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia

  Journal of Clinical Oncology · 2022 · 72 citations

  PURPOSE: Nonresponse and relapse after CD19-chimeric antigen receptor (CAR) T-cell therapy continue to challenge survival outcomes. Phase II landmark data from the ELIANA trial demonstrated nonresponse and relapse rates of 14.5% and 28%, respectively, whereas use in the real-world setting showed nonresponse and relapse rates of 15% and 37%. Outcome analyses describing fate after post-CAR nonresponse and relapse remain limited. Here, we aim to establish survival outcomes after nonresponse and bot…

  DOI

• Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations

  Clinical Trials · 2020 · 55 citations

  1st authorCorresponding

  BACKGROUND/AIMS: The difference in mean survival time, which quantifies the treatment effect in terms most meaningful to patients and retains its interpretability regardless of the shape of the survival distribution or the proportionality of the treatment effect, is an alternative endpoint that could be used more often as the primary endpoint to design clinical trials. The underuse of this endpoint is due to investigators' lack of familiarity with the test comparing the mean survival times and t…

  DOI

• Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium

  Blood Advances · 2022 · 51 citations

  Remarkable complete response rates have been shown with tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy targeting CD19, in patients up to age 26 years with refractory/relapsed B-cell acute lymphoblastic leukemia; it is US Food and Drug Administration approved for this indication. Currently, patients receive a single dose of tisagenlecleucel across a wide dose range of 0.2 to 5.0 × 106 and 0.1 to 2.5 × 108 CAR T cells per kg for patients ≤50 and >50 kg, respectively. The effect…

  DOI

• Impact of the IL-15 superagonist N-803 on lymphatic reservoirs of HIV

  JCI Insight · 2025-06-03 · 8 citations

  articleOpen access

  BACKGROUNDNK cell function is impaired in people with HIV (PWH), hindering their potential to reduce the lymphoid tissue (LT) reservoir. The IL-15 superagonist N-803 has been shown to enhance NK and T cell function and thus may reduce viral reservoirs.METHODSTo determine the impact of N-803 on LTs, we conducted a clinical trial where 10 PWH on effective antiretroviral therapy (ART) were given 3 subcutaneous 6 mcg/kg doses of N-803. We obtained PBMCs and lymph node (LN) and gut biopsies at baseli…

  PublisherOA PDFDOI

• Total Pancreatectomy With Islet Autotransplantation for Chronic Pancreatitis

  Gastroenterology · 2025-06-14 · 6 citations

  article
  PublisherDOI

Frequent coauthors

• Srinath Chinnakotla

  University of Minnesota Medical Center

  176 shared

• Gregory J. Beilman

  176 shared

• Timothy L. Pruett

  University of Minnesota

  176 shared

• Guru Trikudanathan

  University of Minnesota

  176 shared

• Sarah Jane Schwarzenberg

  University of Minnesota Children's Hospital

  176 shared

• Martin L. Freeman

  176 shared

• Jaimie D. Nathan

  176 shared

• Timothy B. Gardner

  Dartmouth–Hitchcock Medical Center

  175 shared

Education

• Ph.D., Public Health

  University of Minnesota

  2000

• M.S., Public Health

  University of Minnesota

  1995

Awards & honors

• Delta Omega, Honorary Society in Public Health, 2020
• Member, Masonic Cancer Center (MCC)

Similar researchers at University of Minnesota

• Weihua Guanh-52
• Joseph Koopmeinersh-46
• Xianghua Luoh-42